| 26.82 0 (0%) | 06-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 36.2 | 1-year : | 42.29 |
| Resists | First : | 31 | Second : | 36.2 |
| Pivot price | 26.6  |
|||
| Supports | First : | 25.8 |
Second : | 22.59 |
| MAs | MA(5) : | 26.7  |
MA(20) : | 26.4 |
| MA(100) : | 20.97 |
MA(250) : | 24.55 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.5 |
| %K %D | K(14,3) : | 38.5 |
D(3) : | 38.5 |
| RSI | RSI(14): 55.3 | |||
| 52-week | High : | 71.5 | Low : | 8.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ QURE ] has closed below upper band by 46.5%. Bollinger Bands are 28% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 27.46 - 27.66 | 27.66 - 27.81 |
| Low: | 25.62 - 25.82 | 25.82 - 25.97 |
| Close: | 26.56 - 26.87 | 26.87 - 27.11 |
uniQure N.V. operates as a specialized gene therapy company, dedicated to pioneering therapeutic solutions for individuals grappling with severe genetic and other debilitating illnesses. The firm's most advanced project, Etranacogene dezaparvovec (designated as AMT-061), is currently progressing through a crucial Phase III pivotal trial, known as HOPE-B, targeting the treatment of hemophilia B. In addition to its flagship program, uniQure is actively developing several other candidates. This includes AMT-130, a gene therapy undergoing Phase I/II clinical assessment for Huntington's disease, and AMT-060, also in Phase I/II clinical trials for hemophilia B. The company's pipeline further extends to AMT-210 for Parkinson's disease, AMT-260 aimed at temporal lobe epilepsy, and AMT-161, which addresses amyotrophic lateral sclerosis. Furthermore, AMT-240 is an early-stage, preclinical product candidate focused on autosomal dominant Alzheimer's disease. Established in 1998, uniQure N.V. maintains its corporate headquarters in Amsterdam, Netherlands.
Thu, 11 Jun 2026
[144] uniQure N.V. SEC Filing - Stock Titan
Thu, 11 Jun 2026
UniQure (NASDAQ: QURE) reports 7,970 RSUs vest and 10,000-share 10b5-1 sale - Stock Titan
Thu, 11 Jun 2026
UniQure N.V. (QURE) files Rule 144 to sell 7,970 RSU shares on 06/11/2026 - Stock Titan
Thu, 11 Jun 2026
Jack Kaye sale notice at UniQure (NASDAQ: QURE) — 7,970 shares proposed - Stock Titan
Wed, 20 May 2026
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Yahoo Finance
Wed, 13 May 2026
Is uniQure N.V. (QURE) A Good Stock To Buy Now? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 5.371e+007 (%) |
| Held by Institutions | 5.5 (%) |
| Shares Short | 11,100 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.7486e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 321.1 % |
| Return on Equity (ttm) | -17 % |
| Qtrly Rev. Growth | 1.809e+007 % |
| Gross Profit (p.s.) | 146.32 |
| Sales Per Share | -262.35 |
| EBITDA (p.s.) | -1.30609e+008 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -172 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 7.31 |
| Dividend | 0 |
| Forward Dividend | 1.03e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|